Rayner partners with Wolffsohn Research to extend its digital health leadership
Posted on 22/02/2022
FEBRUARY 22 2022 – Worthing, United Kingdom. Rayner, a global innovator in cataract and refractive surgery, announced today that it has agreed a development partnership with Wolffsohn Research Ltd to accelerate the development of its Digital Health platform.
Rayner launched RayPRO, a digital platform to collect patient reported outcomes (PRO), in 2019 and has since collected data on over 1,500 IOLs. RayPRO provides their healthcare partners with insights into patient satisfaction as well as specifics on visual outcomes, including spectacle independence (distance, intermediate and near), dysphotopsia, PCO and other valuable indicators. Through this partnership with Wolffsohn Research, Rayner aims to deliver additional platform functionality to RayPRO, based on recent voice of the customer research, whilst partnering on the development of new digital solutions to support and enhance Rayner’s customer experiences.
Commenting on the partnership, Chris Willis, VP Global Marketing, remarked:
“We are thrilled to partner with Professor Wolffsohn and his team to further develop our Digital Health platform. Enhancing RayPRO will improve user experiences and the new product pipeline, including applications to digitally support patients’ use of AEON, our eye drop family designed for use before and after cataract surgery, is extremely exciting.”
Professor James Wolffsohn said, “We are delighted to be entering into a strategic partnership with Rayner to help them deliver their long-term goal of becoming a global leader in Digital Health. Collaboration between companies like Rayner and technology suppliers is increasingly being recognised as key to enabling healthcare transformation and we anticipate that this initiative will allow us not only to increase Rayner’s digital footprint though implementation of additional functionality such as our own Dry-Eye app but will also allow us to dramatically expand their user base. At the heart of this relationship is a desire to broaden Rayner’s digital audience and utilise the benefits linked to the data insights this will provide to patients and surgeons.”
To learn more about RayPRO, visit www.staging.rayner.com/raypro
Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley 1949, Rayner has continuously pioneered intraocular lens (IOL) design with a goal to improve vision and restore sight worldwide. Today, Rayner’s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.
Headquartered in Worthing, United Kingdom, Rayner markets its medical devices, pharmaceuticals and digital solutions worldwide in over 80 countries through a network of distributors and includes direct sales teams in the United Kingdom, USA, India, Poland, Australia, Germany, Austria, Switzerland, France, Italy, Spain and Portugal.
About Wolffsohn Research
As a leading authority within the Ophthalmic field, Professor James Wolffsohn has dedicated his career to academia, research and development. Over recent years, James found it increasingly difficult to identify experienced technical partners to develop user-friendly software and devices to further both his own research and the ophthalmic industry as a whole. To address this, in early 2019 he formed his own company; Wolffsohn Research.
In just 3 short years, Wolffsohn Research has assembled a highly skilled team of engineers, scientists, designers and clinical thought leaders. This agile and cross-functional team of professional problem solvers work with leading industry partners to design, build and regulate cutting edge products. Wolffsohn Research’s approach is to simplify the complex, automating the mundane and use technology to provide a better experience for clinicians and patients alike.